Evidence map›Paper›PMID 11581387›Full record

ArticleJournal of virology2001

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

J D Lifson, J L Rossio, M Piatak, T Parks, L Li, R Kiser, V Coalter, B Fisher, B M Flynn, S Czajak and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed
5.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 264 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. IL-27 effects on HIVFrontiers in virology (Lausanne, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. CD8Nature communications · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

J D LifsonRetroviral Pathogenesis Laboratory, AIDS Vaccine Program, SAIC Frederick, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA. lifson@avpaxpl.ncifcrf.gov
J L Rossio
M Piatak
T Parks
L Li
R Kiser
V Coalter
B Fisher
B M Flynn
S Czajak
V M Hirsch
K A Reimann
J E Schmitz
J Ghrayeb
N Bischofberger
M A Nowak
R C Desrosiers
D Wodarz
Chemical Synthesis Lab · SGBeth Israel Deaconess Medical Center · USInstitute for Advanced Study · USScience Applications International Corporation (United States) · USGilead Sciences (United States) · USHarvard University · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USNew England Biolabs (United States) · US

Funding

OPERATIONS &TECHNICAL SUPPORTN01CO056000 · CO · SCIENCE APPLICATIONS INTERNATIONAL CORP · PI FISCHINGER, PETER J · 1995 to 2000
$95.0M
RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIESR24RR016001 · NCRR · BETH ISRAEL DEACONESS MEDICAL CENTER · PI REIMANN, KEITH A. · 2000 to 2011
$8.1M
IMMUNOLOGIC MECHANISMS CONTROLLING SIV REPLICATIONR01RR013150 · NCRR · BETH ISRAEL DEACONESS MEDICAL CENTER · PI REIMANN, KEITH A · 1997 to 2002
$901k
NCI NIH HHS N01-CO-56000NCRR NIH HHS R01 RR 13150NCRR NIH HHS R24 RR016001NCRR NIH HHS R24 RR 160001
6 · The paper itself

Abstract

Transient antiretroviral treatment with tenofovir, (R)-9-(2-phosphonylmethoxypropyl)adenine, begun shortly after inoculation of rhesus macaques with the highly pathogenic simian immunodeficiency virus (SIV) isolate SIVsmE660, facilitated the development of SIV-specific lymphoproliferative responses and sustained effective control of the infection following drug discontinuation. Animals that controlled plasma viremia following transient postinoculation treatment showed substantial resistance to subsequent intravenous rechallenge with homologous (SIVsmE660) and highly heterologous (SIVmac239) SIV isolates, up to more than 1 year later, despite the absence of measurable neutralizing antibody. In some instances, resistance to rechallenge was observed despite the absence of detectable SIV-specific binding antibody and in the face of SIV lymphoproliferative responses that were low or undetectable at the time of challenge. In vivo monoclonal antibody depletion experiments demonstrated a critical role for CD8(+) lymphocytes in the control of viral replication; plasma viremia rose by as much as five log units after depletion of CD8(+) cells and returned to predepletion levels (as low as <100 copy Eq/ml) as circulating CD8(+) cells were restored. The extent of host control of replication of highly pathogenic SIV strains and the level of resistance to heterologous rechallenge achieved following transient postinoculation treatment compared favorably to the results seen after SIVsmE660 and SIVmac239 challenge with many vaccine strategies. This impressive control of viral replication was observed despite comparatively modest measured immune responses, less than those often achieved with vaccination regimens. The results help establish the underlying feasibility of efforts to develop vaccines for the prevention of AIDS, although the exact nature of the protective host responses involved remains to be elucidated.

Indexed as

OrganophosphonatesAdenineAnimalsAnti-HIV AgentsCD8-Positive T-LymphocytesFemaleMacaca mulattaOrganophosphorus CompoundsSimian Acquired Immunodeficiency SyndromeTenofovirVirus ReplicationAdenineAnti-HIV AgentsOrganophosphonatesOrganophosphorus CompoundsTenofovir

Identifiers

PMID11581387
PMCPMC114593
OpenAlexW2157981287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.